Comparison of tofacitinib, baricitinib, upadacitinib and filgotinib: a 2-year observational study from FIRST registry.

Sonomoto K, Nakayamada S, Sakai H, Ueno M, Tanaka H, Nagayasu A, Aritomi T, Okawara M, Nakata A, Tanaka Y

Open source

DOI: 10.1136/rmdopen-2025-006503
Published: 2026 Jan 16
Container: RMD open
Publisher: Not recorded
Open access: yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
supportingDirectory of Open Access Journals: A matching record was returned by DOAJ. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1136/rmdopen-2025-006503,
  title = {Comparison of tofacitinib, baricitinib, upadacitinib and filgotinib: a 2-year observational study from FIRST registry.},
  author = {Sonomoto K and Nakayamada S and Sakai H and Ueno M and Tanaka H and Nagayasu A and Aritomi T and Okawara M and Nakata A and Tanaka Y},
  year = {2026},
  journal = {RMD open},
  doi = {10.1136/rmdopen-2025-006503},
  url = {https://doi.org/10.1136/rmdopen-2025-006503}
}

RIS

TY  - JOUR
TI  - Comparison of tofacitinib, baricitinib, upadacitinib and filgotinib: a 2-year observational study from FIRST registry.
AU  - Sonomoto K
AU  - Nakayamada S
AU  - Sakai H
AU  - Ueno M
AU  - Tanaka H
AU  - Nagayasu A
AU  - Aritomi T
AU  - Okawara M
AU  - Nakata A
AU  - Tanaka Y
PY  - 2026
JO  - RMD open
DO  - 10.1136/rmdopen-2025-006503
UR  - https://doi.org/10.1136/rmdopen-2025-006503
ER  -

APA

K, S., S, N., H, S., M, U., H, T., A, N., T, A., M, O., A, N., & Y, T. (2026). Comparison of tofacitinib, baricitinib, upadacitinib and filgotinib: a 2-year observational study from FIRST registry.. RMD open. https://doi.org/10.1136/rmdopen-2025-006503

Source records

pubmed · retrieved 2026-09-25T07:02:06.639Z
europe-pmc · retrieved 2026-09-25T07:02:06.635Z
doaj · retrieved 2026-09-25T07:02:06.639Z